Emvision Medical Devices clarifies SPP eligibility for international shareholders

Emvision Medical Devices Ltd (ASX:EMV) announced an update to its proposed securities purchase plan (SPP) on September 17, 2025. The update clarifies that shareholders in New Zealand, United States, United Kingdom, Singapore, Saudi Arabia, Malaysia, Japan, Hong Kong, and Canada will not be eligible to participate in the offer. This correction relates to Section 4F.2 of the announcement.

The SPP offers eligible shareholders the opportunity to acquire new shares at A$1.94 per security in parcels ranging from A$1,000 to A$30,000. The company aims to raise up to A$1 million, with the ability to accept oversubscriptions capped at a total of A$2 million. The maximum total number of ordinary shares that could be issued is 515,464.

Additionally, the SPP includes an offer of attaching options, with three options issued for every four new securities acquired. These options will have an exercise price of A$3.40 and an expiry date two years from their issue date. The maximum number of attaching options that could be issued is 386,598. Funds raised are intended for deployment over FY26 and FY27 to advance the company through major milestones, including supporting FDA submission for the emuTM device and advancing the First Responder program.